The growing practice of inhaling 5meo dimethyltryptamine in Canada presents considerable risks and challenging legal problems. Currently, 5MeO dimethyltryptamine remains a Schedule I substance within Canadian Controlled Drugs and Substances Act, causing its ownership and sale unlawful. While inhalation delivers the compound quickly, it besides pose